WebMar 10, 2024 · Cingulate plans to commence two CTx-1301 Phase 3 clinical studies in 2024: (1) a fixed-dose pediatric and adolescent safety and efficacy study, which will … WebMay 31, 2024 · Cingulate Therapeutics LLC is a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products …
SEC.gov HOME
WebCingulate. Manufacturing · Kansas, United States · <25 Employees . Cingulate is a clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from freq uently diagnosed conditions … WebApr 3, 2024 · Determine whether Cingulate Therapeutics grew or shrank during the last recession. This is useful in estimating the financial strength and credit risk of the company. Compare how recession-proof Cingulate Therapeutics is relative to the industry overall. While a new recession may strike a particular industry, measuring the industry and … church welfare policy
Cingulate Inc. Announces Pricing of $25.0 Million Initial Public …
WebAmendment to Employment Agreement, effective April 1, 2024, between Cingulate Therapeutics LLC and Raul R. Silva Cingulate Inc. Reports First Quarter 2024 Results and Provides Clinical and Business Update Announcement of First Subject Dosing for Anxiety Candidate CTx-2103 to Extend the Application of the Precision Timed Release™ … WebFounders Craig Gilgallon, Matthew Brams, Raul Silva, Shane J Schaffer. Operating Status Active. Last Funding Type Venture - Series Unknown. … WebJul 10, 2024 · Cingulate Therapeutics, LLC is a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit ... church welfare policy pdf